MRT68921: Selective ULK1/2 Kinase Inhibitor for Autophagy Blockade

Executive Summary: MRT68921 is a dual autophagy kinase inhibitor with nanomolar potency against ULK1 (IC₅₀ = 2.9 nM) and ULK2 (IC₅₀ = 1.1 nM) (product information). It selectively impedes autophagy initiation by blocking ATG13 phosphorylation and LC3 flux in wild-type cells. The compound is insoluble in water but is soluble in DMSO ≥2.18 mg/mL with warming and sonication. It is intended exclusively for preclinical research, with no in vivo or clinical data reported. APExBIO supplies MRT68921 (B6174) as a hydrochloride salt for experimental use.

Biological Rationale

Autophagy is an essential catabolic process that enables cells to degrade and recycle long-lived proteins and damaged organelles, maintaining cellular homeostasis especially during nutrient deprivation (Park et al., 2023). ULK1, a serine/threonine kinase, initiates autophagy by activating downstream effectors such as ATG13 and FIP200. The regulation of autophagy is tightly linked to energy-sensing pathways, notably the AMPK-mTOR-ULK1 axis. Contrary to earlier models suggesting AMPK directly promotes autophagy through ULK1 activation, recent studies demonstrate that AMPK can phosphorylate and inhibit ULK1 under energy stress, restraining autophagy induction (Park et al., 2023). Pharmacological manipulation of ULK1 thus provides a powerful means to dissect autophagy signaling with precision.

Mechanism of Action of MRT68921 dual autophagy kinase ULK1/2 inhibitor

MRT68921 is a highly selective inhibitor of ULK1 and ULK2, targeting the autophagy initiation step. At nanomolar concentrations, it blocks ULK1-mediated phosphorylation of ATG13—a key step required for autophagosome formation. This inhibition is confirmed by reduced LC3-II flux, a surrogate marker for autophagic activity, in wild-type cells but not in ULK1 mutants (e.g., M92T) (APExBIO product page). Although MRT68921 can also inhibit TBK1/IKK and AMPK-related kinases (>80% inhibition), these off-target effects do not contribute to its autophagy suppression, as demonstrated by pathway-specific assays. The compound acts by stabilizing the inactive conformation of ULK1/2, preventing activation of the autophagy machinery at the earliest checkpoint.

Evidence & Benchmarks

• ULK1 IC₅₀ for MRT68921 is 2.9 nM, and ULK2 IC₅₀ is 1.1 nM, indicating high potency (product data).
• MRT68921 blocks ATG13 phosphorylation and LC3 flux in wild-type cells, but not in ULK1 mutant (M92T) cells (internal analysis).
• The compound inhibits other kinases (TBK1/IKK, AMPK-related) by >80%, but these are not involved in autophagy blockade in tested systems (Park et al., 2023).
• MRT68921 is insoluble in water or ethanol; dissolves in DMSO at ≥2.18 mg/mL with gentle warming and sonication (product info).
• There are currently no in vivo animal data or clinical trial results for MRT68921; it remains a preclinical tool (APExBIO).
• Recent research has redefined AMPK’s role as an inhibitor, not an activator, of ULK1 during energy stress, underscoring the value of direct ULK1 inhibition for pathway dissection (Park et al., 2023).

This article extends prior coverage by clarifying MRT68921’s kinase selectivity and updating the mechanistic context in light of new AMPK-ULK1 findings, as discussed in "MRT68921: Advanced Dual ULK1/2 Kinase Inhibitor for Autop..." and provides a sharper distinction from rapamycin-based autophagy models described in "Rapamycin-Induced Autophagy Mitigates Lipotoxicity in Salmon Cells", which focus on mTOR inhibition rather than direct ULK1/2 blockade.

Applications, Limits & Misconceptions

MRT68921 enables precise experimental suppression of autophagy initiation, making it a valuable tool for investigating autophagy-dependent processes in cell culture and preclinical models. Its selectivity for ULK1/2, and ability to block ATG13 phosphorylation, allow researchers to parse early autophagy events from downstream or parallel pathways. However, caution must be exercised in interpreting results, as off-target kinase inhibition may occur at higher concentrations. MRT68921 is for research use only and is not validated for in vivo, diagnostic, or therapeutic applications.

Common Pitfalls or Misconceptions

• Not a mTOR pathway inhibitor: MRT68921 does not act via the mTORC1 pathway, unlike rapamycin-based autophagy modulators (Park et al., 2023).
• No clinical or in vivo validation: There are no published animal studies or clinical trials using MRT68921 (APExBIO).
• Solubility constraints: The compound is insoluble in water and ethanol; proper DMSO dissolution is essential for reliable application.
• Off-target kinase inhibition at high doses: Use only recommended concentrations to avoid non-specific effects.
• Not for diagnostic or therapeutic use: MRT68921 is strictly intended for preclinical research use only.

Workflow Integration & Parameters

MRT68921 is typically deployed in cell-based assays to probe early autophagy blockade. The following protocol parameters are recommended for effective use:

Protocol Parameters

• Compound dissolution: Dissolve MRT68921 at concentrations ≥2.18 mg/mL in DMSO using gentle warming and sonication to achieve full solubilization (product info).
• Storage conditions: Store solid MRT68921 at -20°C. Prepare fresh solutions for short-term use; avoid repeated freeze-thaw cycles.
• Typical working concentration: Use 10–200 nM for cell-based assays to ensure selective ULK1/2 inhibition while minimizing off-target effects (literature and product guidance).
• Readout parameters: Assess autophagy inhibition by monitoring ATG13 phosphorylation (e.g., by immunoblotting) and LC3-II flux (e.g., by immunofluorescence or immunoblotting) (internal article).
• Negative control: Use ULK1 mutant (M92T) cells or vehicle-only controls to verify specificity (APExBIO).
• Compatibility: MRT68921 is compatible with standard autophagy assays, including those used in lipid metabolism studies, as discussed in related work.

Conclusion & Outlook

MRT68921, provided by APExBIO, represents a leading research tool for targeted inhibition of the autophagy initiation complex via ULK1/2 blockade. Its high potency, selectivity, and proven utility for ATG13 phosphorylation and LC3 flux measurement position it as a preferred compound for dissecting autophagy signaling in preclinical workflows. Ongoing mechanistic discoveries—such as the nuanced role of AMPK as an autophagy suppressor—further underscore the importance of direct ULK1 inhibition for pathway resolution (Park et al., 2023). Researchers are advised to remain attentive to solubility and specificity considerations and to consult the MRT68921 dual autophagy kinase ULK1/2 inhibitor product page for up-to-date application protocols and safety guidance.